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Objectives. The purpose of the present study is to verify if the degree of immunological response against metastatic tumors,
measured by the number of CD57+ NK-cells in the tissue of a brain metastasis, inﬂuences the later development of new brain
metastases or tumor recurrence. Patients and Methods.C D 5 7 + NK-cells were immunohistochemically identiﬁed in the resected
tumor, in a series of twenty patients operated on by a single brain metastasis secondary to lung adenocarcinoma. In each case, the
degree of CD57+ NK-cells inﬁltration within the tumor tissue and the period free of new intracranial disease after brain surgery
were recorded. Results. All the studied tumors showed variable number of CD57+ NK-cells (mean ± standard deviation: 8.4 ± 4.8
per microscopical ﬁeld, at 200x). The period free of intracranial disease ranged between 10 and 52 weeks (mean ± standard
deviation: 22.7 ±11.9). Statistical analysis showed that there was no correlation between the degree of NK-cells inﬁltration within
the resected tumor and the period free of intracranial disease after surgery (P>0.05). Conclusion. This ﬁnding supports that
clinical behavior in metastatic brain disease is not inﬂuenced by the immunological response mediated by CD57+ NK-cells.
1.Introduction
At present, it is accepted that Natural Killer (NK) cells are a
subset of lymphocytes with an important role in the early
response to tumors [1, 2]. They destroy tumor cells by
twomaincytotoxicpathways:aperforin/granzyme-mediated
secretory mechanism and a TNF-family ligand-mediated
apoptotic killing. While the former mechanism acts mainly
against cultured leukemia cell targets, the second is the way
for which NK-cells act against most tumor cell targets [3–6].
Furthermore, the ﬁnding that the number of intratumoral
CD57+ NK-cells inﬂuences the survival of the patients has
been described for patients with gastric carcinoma [7]o r
squamous lung cancer [8] supporting the biological eﬀect
of immunological defense mechanism mediated by NK-cells.
On the other hand, it is well-known that immunologic
manipulation, in an early phase of carcinogenesis, can
modulate the tumor development [9].
Since NK-cells represent a defense against tumors, it is
logical to suppose that the capacity to act against tumors
through NK-cells will determine the biggest or smaller eas-
iness with which a tumor developed. Therefore, if a patient
shows strong immunological defense mechanisms by means
of NK-cells in the tissue of a brain metastasis, it is logical to
suppose that the tumor recurrence or the development of a
new cerebral metastasis will be more diﬃcult.
In a previous study, we concluded that the number of
CD57+ NK-cells in the tumor stroma of brain metastases
does not correlate with the number of apoptotic tumor cells.
This ﬁnding suggests that, in brain metastases, apoptosis
related to immune response is mainly mediated by activated
tumor-inﬁltrating mononuclear cells other than CD57+ NK-
cells [10]. We studied here if the number of CD57+ NK-cells
within the tumor tissue of brain metastases inﬂuences the
clinical behavior, in terms of inﬂuencing the capacity of the
braintobeprotectedforthedevelopmentofanewmetastasis
or tumor recurrence.2 International Journal of Surgical Oncology
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Figure 1: Examples of CD57+ NK-cells in the resected brain metastases of the series. NK-cells were generally distributed surrounding the
vessels (a) and within the tumor stroma (b). Immunostained CD57+ NK-cells can be seen (×200).
2.MaterialsandMethods
For this study we selected twenty male patients operated on
because of a single cerebral metastasis from lung adenocar-
cinoma and that developed local recurrence or new brain
metastases after surgery. In all cases tumor resection was
considered complete, and the patients received holocraneal
radiotherapy (30–40Gy in 10–20 fractions) after surgery.
The age at time of surgery ranged between 42 and 78 years
(mean: 64 years).
Paraﬃn-embedded specimens from the resected tumors
were studied. A ﬁrst study (unpublished data) showed that
in all resected tumors, a variable number of cells expressed
CD95 (Fas/APO1). From each tumor, a histological slice
was processed by haematoxylin-eosin (HE) technique for
studying both the histological pattern of the tumor and the
degree and distribution of lymphocytic inﬁltration. Another
adjacent histological slice was processed for immunohisto-
chemical expression of CD57. In brief, histological sections
from paraﬃn-embedded samples were mounted on glass
slides and were deparaﬃnized by treatment in xylene for 15
minutes. The sections were rehydrated in a graded ethanol
series and rinsed in phosphate-buﬀered saline (PBS) at pH
7.4. Then, sections were trypsinized for 15 minutes and
rinsed in PBS. The slides were then washed in citrate-
buﬀered solution (pH 6.0) for 10 minutes on microwave and
then placed in hydrogen peroxide 3% in methanol for 15
minutes in order to block endogenous peroxidase activity,
and the sections were immersed in PBS. For detection of
NK-cells, primary monoclonal antibody to CD57 (1:100,
Master Diagnostica, Granada, Spain) was used. Monoclonal
antibody was added overnight at 4◦Co nw e tc h a m b e r ,
and the histological slices were again rinsed in PBS. A
30-minute incubation with biotinyled secondary antibody
at 37◦C was followed by a standard PBS rinse. Another 30-
minute incubation with streptavidin-peroxidase complex, at
37◦C, was carried out, and then chromogen solution was
added (diaminobenzidine). After it, the slices were stained
with hematoxylin, mounted, and examined microscopically.
In all cases, negative controls were performed using rabbit
normal serum as primary antibody. For each tumor, the
number of CD57-immunostained cells was counted at least
on 10 randomized histological ﬁelds, at 200x, and then
averaged. In all cases, the evaluation of the number of NK-
cells per ﬁeld was conducted by two investigators with no
previous knowledge of the case from each sample obtained.
Generally a high grade of agreement between the observers
was obtained, but, in any case, the means of values recorded
by these investigators were recorded as ﬁnal values.
3. Results
All the tumors of the series showed variable number of
CD57+ NK-cells. These cells did not show a uniform
distribution in the tumor but were usually grouped around
blood vessels or within the tumor stroma (Figure 1).
After a randomized study of diﬀerent ﬁelds from each
tumor, at 200x, a number of 8.4 ± 4.8 (mean ± standard
deviation) CD57+ N K - c e l l sw a se s t i m a t e da sa na v e r a g e d
value (Figure 2(a)) in the series. On the other hand, the
period of time free of new cerebral metastases or local tumor
recurrence in the patients of the series ranged between 10
and 52 weeks (mean ± standard deviation: 22.7 ± 11.9)
(Figure 2(b)).
Lastly, we analyzed for each case the correlation between
the time free of local recurrence or new intracranialInternational Journal of Surgical Oncology 3
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Figure 2: (a) Distribution of the mean values of CD57+ NK-cells by microscopical ﬁeld, at 200x, in the tumors of the series. (b) Time free
of local recurrence or new intracranial metastases, in the cases of the series.
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Figure 3: Correlation between the degree of CD57+ NK-cells in the
resected metastasis and the time free of new intracranial metastatic
disease in the cases of the series. Correlation was not found (P =
0.63; correlation coeﬃcient (r): −0.1128; 95% conﬁdence interval
(CI): −0.52 to 0.34).
mestastases after surgery and the degree of CD57+ NK-cells
inﬁltrating the resected brain metastasis. After this analysis,
a correlation between these two variables could not be
found (P = 0.63; correlation coeﬃcient (r): −0.1128; 95%
conﬁdence interval: −0.52 to 0.34) (Figure 3).
4. Discussion
For the present study, we have identiﬁed CD57+ NK-cells in
the tissue of resected brain metastases, in a homogeneous
series of metastatic brain tumors developed as a result
of the spread of a lung adenocarcinoma. Furthermore, in
each case, we have recorded the time free of local tumor
recurrence or appearance of new cerebral metastases after
treatment. Although cytotoxic eﬃcacy of NK-cells in tumor
tissue may not be judged by their numerical presence, it
is accepted that these cells play an important role in the
immunological defense against tumor cells. Thus, it seems
logical to assume a relationship between the degree of
NK-cells inﬁltration in tumor tissue and the eﬀectiveness of
t h i st y p eo fi m m u n o l o g i c a ld e f e n s e .
On the other hand, it is accepted that the main mecha-
nism for which NK-cells act is through inducing apoptosis
in the tumor cells [3–6] ,a n dw ep r e v i o u s l yo b t a i n e di na l l
the tumors of the series (data not shown) variable expression
of CD95 (Fas/APO1), a 48-kD transmembrane glycoprotein,
at present identiﬁed as an important mediator in the apop-
totic process mediated by NK-cells. Although this ﬁnding
suggested the possible susceptibility of tumors to the action
of inﬁltrating NK-cells, in a previous study, we concluded
that the number of NK-cells that are present in the stroma
of brain metastases does not correlate with the number of
apoptotic tumor cells [10]. Therefore, it is possible that NK-
cells do not play an important role in the immunological
defense against brain metastases. The purpose of the present
study is to add new data to this hypothesis, verifying if the
degree of local immunological response against a metastatic
brain tumor, measured by the degree of NK-cell inﬁltration
within the tumor tissue, inﬂuences the clinical behavior,
in terms of inﬂuencing the capacity of the brain to be
protected for the development of new metastases or local
tumor recurrence. Our present results showed that the time
free of new cerebral aﬀectation for metastatic dissemination
or recurrence of the previously resected tumor is not related
with the degree of immunological response mediated by the
presence of NK-cells. Although it is obvious that our present
series has scarce number of cases and that multiple factors,
mainly the evolution of the systemic disease, can inﬂuence
the clinical behavior of patients suﬀering metastatic brain
disease, we think that our present analysis represents a new
argument supporting that in brain metastases, the immune
response mediated by CD57+ NK-cells plays a doubtful role.
This consideration should be kept in mind in therapeutic
trials based on the hypothetical defensive action of the NK-
cells against metastatic brain tumors.4 International Journal of Surgical Oncology
5. Conclusion
Our present ﬁndings suggest that clinical behavior in
metastatic brain disease is not inﬂuenced by the immuno-
logical response mediated by CD57+ NK-cells.
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